Healthcare Industry News: RT Technology
News Release - March 8, 2007
HemoSense Signs Agreement for INRatio Distribution in CanadaSAN JOSE, Calif.--(HSMN NewsFeed)--HemoSense, Inc. (AMEX:HEM ) today announced that it has signed an agreement with ManthaMed, a Canadian provider of health screening, monitoring and diagnostic testing technologies, to market and distribute HemoSense's portable INRatioŽ PT/INR monitoring system for patient self-testing and healthcare professionals in Canada. The agreement with ManthaMed represents the Company's 16th international distribution agreement and expands HemoSense's international distribution reach to 23 countries.
"We believe that entry into the Canadian market represents a significant growth opportunity with an estimated 600,000 patients on warfarin therapy," said Timothy Still, executive VP and chief commercial officer of HemoSense. "ManthaMed's experience in point-of-care diagnostics and patient monitoring make INRatio a natural addition to their product line."
Peter Mantha, president of ManthaMed added, "As a distributor devoted to improving patient access to reliable and accurate medical technologies, we are delighted to introduce the INRatio system to the Canadian market. We trust that many professionals in physicians' offices and anticoagulation patients who self-test at home will find INRatio a convenient and appealing alternative to traditional laboratory testing methods."
HemoSense is a point-of-care diagnostic healthcare company that develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatioŽ system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com.
ManthaMed is a privately-owned Canadian company with offices in Mississauga, Ontario. ManthaMed distributes diagnostic and monitoring solutions throughout Canada providing state-of-the-aRT Technology and point-of-care management tools designed to evaluate the risk factors of cardiovascular and respiratory disease. These monitoring solutions are provided to patients and healthcare professionals. ManthaMed's current products include: clinical blood pressure monitors, lipid and glucose management systems, ultrasound dopplers and spirometers. For more information, visit www.manthamed.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, statements regarding the Company's ability to grow significantly as a result of entry into the Canadian market are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its Form 10-Q filed on February 13, 2007. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
HemoSenseŽ and INRatioŽ are registered trademarks of HemoSense, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.